Who are CGT9486 plus sunitinib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gilteritinib (GILT), Letybo®, CGT9486, ICP-488, Gilteritinib + Azacitidine + Venetoclax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cgt9486-plus-sunitinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

CGT9486 plus sunitinib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CGT9486 plus sunitinib (CGT9486 plus sunitinib) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: FLT3 inhibitor; multi-targeted tyrosine kinase inhibitor. Area: Oncology.

phase 3 FLT3 inhibitor; multi-targeted tyrosine kinase inhibitor FLT3; PDGFR; KIT; VEGFR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CGT9486 plus sunitinib (CGT9486 plus sunitinib) — Cogent Biosciences, Inc.. CGT9486 is a selective FLT3 inhibitor combined with sunitinib, a multi-targeted tyrosine kinase inhibitor, to block FLT3 and PDGFR signaling in acute myeloid leukemia.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CGT9486 plus sunitinib TARGET	CGT9486 plus sunitinib	Cogent Biosciences, Inc.	phase 3	FLT3 inhibitor; multi-targeted tyrosine kinase inhibitor	FLT3; PDGFR; KIT; VEGFR
Gilteritinib (GILT)	Gilteritinib (GILT)	Technische Universität Dresden	marketed	FLT3 inhibitor	FLT3 (FMS-like tyrosine kinase 3)
Letybo®	Letybo®	Yuvell	marketed	FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor	FLT3, JAK2
CGT9486	CGT9486	Cogent Biosciences, Inc.	phase 3	FLT3 inhibitor	FLT3
ICP-488	ICP-488	Beijing InnoCare Pharma Tech Co., Ltd.	phase 3	FLT3 inhibitor	FLT3
Gilteritinib + Azacitidine + Venetoclax	Gilteritinib + Azacitidine + Venetoclax	Institute of Hematology & Blood Diseases Hospital, China	phase 3	FLT3 inhibitor + hypomethylating agent + BCL-2 inhibitor combination	FLT3, DNA methyltransferase, BCL-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (FLT3 inhibitor; multi-targeted tyrosine kinase inhibitor class)

Cogent Biosciences, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CGT9486 plus sunitinib — Competitive Intelligence Brief. https://druglandscape.com/ci/cgt9486-plus-sunitinib. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing